Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
18 April 2023 - 9:17PM
Business Wire
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the
“Company” or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases and biodefense, today announced
that Dr. Don Cilla, Appili President and Chief Executive Officer,
will present at the Bloom Burton & Co. Healthcare Investor
Conference taking place on April 25 and 26, 2023.
The presentation will include an update on Appili’s pipeline of
novel anti-infectives; ATI-1701, a vaccine for tularemia being
funded by the U.S. Government through IND submission and ATI-1801,
a treatment for cutaneous leishmaniasis, a disfiguring infection of
the skin. Appili believes that both programs may be eligible to
receive FDA Priority Review Vouchers upon approval.
Presentation details are as follows: Date: Wednesday,
April 26, 2023 Time: 3:30 pm ET Location: Metro
Toronto Convention Centre, 255 Front St W, Toronto, Ontario
Appili management will also be conducting one-on-one meetings
throughout the conference. To request a one-on-one meeting, please
register for the conference here.
About Bloom Burton & Co. Bloom Burton & Co. is a
firm dedicated to accelerating returns in the healthcare sector for
both investors and companies. Bloom Burton has an experienced team
of medical, scientific, industry and capital markets professionals
who perform a deep level of diligence, which combined with our
creative and entrepreneurial approach, assists our clients in
achieving the right monetization events. Bloom Burton and its
affiliates provide capital raising, M&A advisory, equity
research, business strategy and scientific consulting, as well as
advisory on direct investing, company creation and incubation
services. Bloom Burton Securities Inc. is a member of the
Investment Industry Regulatory Organization of Canada (IIROC) and
is also a member of the Canadian Investor Protection Fund
(CIPF).
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical
company that is purposefully built, portfolio-driven, and
people-focused to fulfill its mission of solving life-threatening
infections. By systematically identifying urgent infections with
unmet needs, Appili’s goal is to strategically develop a pipeline
of novel therapies to prevent deaths and improve lives. The Company
is currently advancing a diverse range of anti-infectives,
including a vaccine candidate to eliminate a serious biological
weapon threat, a topical antiparasitic for the treatment of a
disfiguring disease, and a novel easy to use, liquid oral
formulation targeting parasitic and anaerobic infections. Led by a
proven management team, Appili is at the epicenter of the global
fight against infection. For more information, visit
www.AppiliTherapeutics.com.
Forward looking statements
This news release contains “forward-looking statements”,
including with respect to potential PRV eligibility for ATI-1701
and ATI-1801. Wherever possible, words such as “may “, “would”,
“could “, “should”, “will,” “anticipate,” “believe,” “plan,”
“expect,” “intend,” “estimate,” “potential for” and similar
expressions have been used to identify these forward-looking
statements. These forward-looking statements reflect the current
expectations of the Company’s management for future growth, results
of operations, performance and business prospects and opportunities
and involve significant known and unknown risks, uncertainties and
assumptions, including, without limitation, those risks listed in
the annual information form of the Company dated June 29, 2022 and
the other filings made by the Company with the Canadian securities
regulatory authorities (which may be viewed at www.sedar.com).
Should one or more of these risks or uncertainties materialize or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. The Company
disclaims any intention or obligation to revise forward-looking
statements whether as a result of new information, future
developments or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230417005907/en/
Media: Jenna McNeil, Communications Manager Appili
Therapeutics E: JMcNeil@AppiliTherapeutics.com Investor
Relations: Don Cilla, Pharm.D., M.B.A., President and CEO
Appili Therapeutics E: Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Jul 2023 to Jul 2024